Abstract | BACKGROUND: PATIENTS AND METHODS: RESULTS: The incidence of CNS metastases as first site of disease progression was similar between arms; placebo arm: 51 of 406 (12.6%), pertuzumab arm: 55 of 402 (13.7%). Median time to development of CNS metastases as first site of disease progression was 11.9 months in the placebo arm and 15.0 months in the pertuzumab arm; hazard ratio (HR) = 0.58, 95% confidence interval (CI) 0.39-0.85, P = 0.0049. Overall survival in patients who developed CNS metastases as first site of disease progression showed a trend in favor of pertuzumab, trastuzumab, and docetaxel; HR = 0.66, 95% CI 0.39-1.11. Median overall survival was 26.3 versus 34.4 months in the placebo and pertuzumab arms, respectively. Treatment comparison of the survival curves was not statistically significant for the log-rank test (P = 0.1139), but significant for the Wilcoxon test (P = 0.0449). CONCLUSIONS: CLINICALTRIALSGOV: NCT00567190.
|
Authors | S M Swain, J Baselga, D Miles, Y-H Im, C Quah, L F Lee, J Cortés |
Journal | Annals of oncology : official journal of the European Society for Medical Oncology
(Ann Oncol)
Vol. 25
Issue 6
Pg. 1116-21
(Jun 2014)
ISSN: 1569-8041 [Electronic] England |
PMID | 24685829
(Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. |
Chemical References |
- Antibodies, Monoclonal, Humanized
- Taxoids
- Docetaxel
- ERBB2 protein, human
- Receptor, ErbB-2
- pertuzumab
- Trastuzumab
|
Topics |
- Adult
- Aged
- Antibodies, Monoclonal, Humanized
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Breast Neoplasms
(drug therapy, mortality, pathology)
- Central Nervous System Neoplasms
(epidemiology, secondary)
- Docetaxel
- Double-Blind Method
- Female
- Humans
- Incidence
- Kaplan-Meier Estimate
- Middle Aged
- Proportional Hazards Models
- Receptor, ErbB-2
(genetics)
- Taxoids
(administration & dosage)
- Trastuzumab
|